Affinity Asset Advisors, LLC 13F holdings
Affinity Asset Advisors, LLC reported 100 positions with a total reported value of $2.0B as of 2026-06-30, in its 13F for Q2 2026, filed 2026-08-13. Top holdings by reported value: ROIV ROIVANT SCIENCES LTD (6.6%), APGE APOGEE THERAPEUTICS INC (6.5%), SYRE SPYRE THERAPEUTICS INC (5.6%), XENE XENON PHARMACEUTICALS INC (4.8%), ERAS ERASCA INC (4.8%). Against 2026-03-31 it opened 16 new positions and exited 7. Next 13F due by 2026-11-14, the legal deadline 45 days after the quarter ending 2026-09-30.
Email me when Affinity Asset Advisors, LLC files its 13F
A free account follows up to 10 funds. New 13F filings arrive in your daily or weekly digest. No password and no card.
Top holdings
25 largest of 100 positions · reported value as of 2026-06-30
| Holding | Shares | Reported value | % of portfolio |
|---|---|---|---|
| ROIV ROIVANT SCIENCES LTD | 3,750,000 | $132.7M | 6.6% |
| APGE APOGEE THERAPEUTICS INC | 987,000 | $131.0M | 6.5% |
| SYRE SPYRE THERAPEUTICS INC | 1,279,134 | $113.6M | 5.6% |
| XENE XENON PHARMACEUTICALS INC | 1,595,000 | $96.3M | 4.8% |
| ERAS ERASCA INC | 5,250,000 | $96.2M | 4.8% |
| INSM INSMED INC | 650,000 | $69.3M | 3.4% |
| PRAX PRAXIS PRECISION MEDICINES I | 185,000 | $61.9M | 3.1% |
| ALKS ALKERMES PLC | 1,125,000 | $58.9M | 2.9% |
| ORKA ORUKA THERAPEUTICS INC | 590,000 | $56.2M | 2.8% |
| ANAB ANAPTYSBIO INC | 826,109 | $55.8M | 2.8% |
| AVTX AVALO THERAPEUTICS INC | 2,900,000 | $53.6M | 2.7% |
| CYTK CYTOKINETICS INC | 550,000 | $46.9M | 2.3% |
| RVMD REVOLUTION MEDICINES INC | 250,000 | $46.8M | 2.3% |
| ABVX ABIVAX SA | 330,000 | $44.0M | 2.2% |
| TRAX FIRST TRACKS BIOTHERAPEUTICS | 2,032,012 | $40.9M | 2.0% |
| DNTH DIANTHUS THERAPEUTICS INC | 400,000 | $39.0M | 1.9% |
| STRO SUTRO BIOPHARMA INC | 1,172,487 | $38.9M | 1.9% |
| NUVL NUVALENT INC | 275,000 | $34.0M | 1.7% |
| TRVI TREVI THERAPEUTICS INC | 1,800,172 | $33.6M | 1.7% |
| OVID OVID THERAPEUTICS INC | 10,144,562 | $27.3M | 1.4% |
| LXEO LEXEO THERAPEUTICS INC | 5,807,611 | $27.0M | 1.3% |
| CLDX CELLDEX THERAPEUTICS INC NEW | 700,000 | $26.0M | 1.3% |
| BLTE BELITE BIO INC | 165,000 | $25.4M | 1.3% |
| ELVN ENLIVEN THERAPEUTICS INC | 500,000 | $25.4M | 1.3% |
| FBRX FORTE BIOSCIENCES INC | 1,145,391 | $24.3M | 1.2% |
SEC FORM 13F · Q2 2026 · VALUES AS REPORTED, NOT PRICES
New positions this quarter
Held at 2026-06-30, not at 2026-03-31 · 16 in all · reported value as of 2026-06-30
| Holding | Shares | Reported value | % of portfolio |
|---|---|---|---|
| TRAX FIRST TRACKS BIOTHERAPEUTICS | 2,032,012 | $40.9M | 2.0% |
| IDYA IDEAYA BIOSCIENCES INC | 400,000 | $14.9M | 0.7% |
| ODTX ODYSSEY THERAPEUTICS INC | 766,346 | $14.3M | 0.7% |
| QURE UNIQURE NV | 175,000 | $8.1M | 0.4% |
| ASMB ASSEMBLY BIOSCIENCES INC | 190,000 | $5.2M | 0.3% |
| COAG HEMAB THERAPEUTICS HLDGS INC | 138,030 | $5.1M | 0.3% |
| RACC RESEARCH ALLIANCE CORP III | 370,000 | $4.0M | 0.2% |
| AMAN AMANAT ACQUISITION CORP | 375,000 | $3.8M | 0.2% |
| BHVN BIOHAVEN LTD | 250,000 | $3.7M | 0.2% |
| FTH FAETH THERAPEUTICS INC | 144,404 | $3.6M | 0.2% |
| JATT JATT II ACQUISITION CORP | 200,000 | $2.3M | 0.1% |
| NMRA NEUMORA THERAPEUTICS INC. | 1,070,651 | $1.8M | <0.1% |
| AMLX AMYLYX PHARMACEUTICALS INC | 98,999 | $1.8M | <0.1% |
| SPRB SPRUCE BIOSCIENCES INC | 30,000 | $1.6M | <0.1% |
| EIKN EIKON THERAPEUTICS INC | 98,001 | $1.3M | <0.1% |
| BOLD BOUNDLESS BIO INC | 250,000 | $625.0K | <0.1% |
Sold out
Held at 2026-03-31, gone by 2026-06-30 · 7 in all · reported value as of 2026-03-31
| Holding | Shares 2026-03-31 | Reported value | % of portfolio then |
|---|---|---|---|
| CENTESSA PHARMACEUTICALS PLC | 1,400,000 | $55.6M | 3.3% |
| ARCELLX INC | 362,764 | $41.7M | 2.5% |
| TERNS PHARMACEUTICALS INC | 562,631 | $29.7M | 1.8% |
| BBIO BRIDGEBIO PHARMA INC | 150,000 | $11.1M | 0.7% |
| WVE WAVE LIFE SCIENCES LTD | 1,401,727 | $10.2M | 0.6% |
| CORT CORCEPT THERAPEUTICS INC | 50,000 | $2.0M | 0.1% |
| KEZAR LIFE SCIENCES INC | 229,076 | $1.7M | 0.1% |
Biggest increases and decreases
Positions held at both quarter ends, by change in shares · reported value as of 2026-06-30
Increases
| Holding | Shares 2026-03-31 | Shares 2026-06-30 | Change | Reported value |
|---|---|---|---|---|
| ROIV ROIVANT SCIENCES LTD | 2,800,000 | 3,750,000 | +33.9% | $132.7M |
| AVTX AVALO THERAPEUTICS INC | 1,340,840 | 2,900,000 | +116.3% | $53.6M |
| RVMD REVOLUTION MEDICINES INC | 100,000 | 250,000 | +150.0% | $46.8M |
| INSM INSMED INC | 480,000 | 650,000 | +35.4% | $69.3M |
| BLTE BELITE BIO INC | 65,000 | 165,000 | +153.8% | $25.4M |
| SGMT SAGIMET BIOSCIENCES INC | 868,020 | 2,497,864 | +187.8% | $19.3M |
| RLAY RELAY THERAPEUTICS INC | 400,000 | 1,050,000 | +162.5% | $19.6M |
| ANRO ALTO NEUROSCIENCE INC | 500,000 | 850,000 | +70.0% | $22.4M |
| EQ EQUILLIUM INC | 1,226,310 | 4,100,000 | +234.3% | $13.1M |
| ORKA ORUKA THERAPEUTICS INC | 499,673 | 590,000 | +18.1% | $56.2M |
| CLDX CELLDEX THERAPEUTICS INC NEW | 500,000 | 700,000 | +40.0% | $26.0M |
| PROQR THRAPEUTICS N V | 2,454,278 | 5,543,936 | +125.9% | $10.3M |
Decreases
| Holding | Shares 2026-03-31 | Shares 2026-06-30 | Change | Reported value |
|---|---|---|---|---|
| APGE APOGEE THERAPEUTICS INC | 1,284,926 | 987,000 | -23.2% | $131.0M |
| TEVA TEVA PHARMACEUTICAL INDS LTD | 1,400,000 | 374,000 | -73.3% | $12.7M |
| ASND ASCENDIS PHARMA A/S | 95,000 | 30,000 | -68.4% | $8.0M |
| CYTK CYTOKINETICS INC | 700,483 | 550,000 | -21.5% | $46.9M |
| ALKS ALKERMES PLC | 1,350,000 | 1,125,000 | -16.7% | $58.9M |
| COGT COGENT BIOSCIENCES INC | 750,000 | 450,000 | -40.0% | $17.4M |
| CMPS COMPASS PATHWAYS PLC | 1,108,483 | 301,183 | -72.8% | $4.3M |
| ABVX ABIVAX SA | 405,000 | 330,000 | -18.5% | $44.0M |
| MDGL MADRIGAL PHARMACEUTICALS INC | 55,000 | 40,000 | -27.3% | $21.5M |
| ANAB ANAPTYSBIO INC | 940,000 | 826,109 | -12.1% | $55.8M |
| ZURA ZURA BIO LTD | 2,564,303 | 1,464,303 | -42.9% | $8.6M |
| XENE XENON PHARMACEUTICALS INC | 1,675,000 | 1,595,000 | -4.8% | $96.3M |
CIK 1773195 · 13F FILINGS ON EDGAR · INFORMATIONAL ONLY
